The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
NEJM study shows strong protection across strains
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The leading cancer hospital urges carrier screening to prevent thalassemia burden
Subscribe To Our Newsletter & Stay Updated
